PubMed

Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration.

Hopley C, Salkeld G, Mitchell P.

Br J Ophthalmol. 2004 Aug;88(8):982-7.PMID: 15258009 [PubMed - indexed for MEDLINE]Related articlesFree article

The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration.

Sharma S, Brown GC, Brown MM, Hollands H, Shah GK.

Ophthalmology. 2001 Nov;108(11):2051-9.PMID: 11713079 [PubMed - indexed for MEDLINE]Related articles

The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration--a value-based reappraisal with 5-year data.

Brown GC, Brown MM, Campanella J, Beauchamp GR.

Am J Ophthalmol. 2005 Oct;140(4):679-87.PMID: 16226519 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.

Earnshaw SR, Moride Y, Rochon S.

Clin Ther. 2007 Sep;29(9):2096-106; discussion 2094-5.PMID: 18035208 [PubMed - indexed for MEDLINE]Related articles

Computerized model of cost-utility analysis for treatment of age-related macular degeneration.

Fletcher EC, Lade RJ, Adewoyin T, Chong NV.

Ophthalmology. 2008 Dec;115(12):2192-8. Epub 2008 Oct 18.PMID: 18930556 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of photodynamic therapy with verteporfin for age related macular degeneration: the UK case.

Smith DH, Fenn P, Drummond M.

Br J Ophthalmol. 2004 Sep;88(9):1107-12.PMID: 15317697 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.

Hernandez-Pastor LJ, Ortega A, Garcia-Layana A, Giraldez J.

Clin Ther. 2008 Dec;30(12):2436-51.PMID: 19167602 [PubMed - indexed for MEDLINE]Related articles

Cost utility of screening and treatment for early age related macular degeneration with zinc and antioxidants.

Hopley C, Salkeld G, Wang JJ, Mitchell P.

Br J Ophthalmol. 2004 Apr;88(4):450-4.PMID: 15031152 [PubMed - indexed for MEDLINE]Related articlesFree article

A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.

Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.

Ophthalmology. 2007 Jun;114(6):1170-8. Epub 2007 Feb 23.PMID: 17320964 [PubMed - indexed for MEDLINE]Related articles

Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.

Colquitt JL, Jones J, Tan SC, Takeda A, Clegg AJ, Price A.

Health Technol Assess. 2008 May;12(16):iii-iv, ix-201. Review.PMID: 18462575 [PubMed - indexed for MEDLINE]Related articlesFree article

Using contrast sensitivity to estimate the cost-effectiveness of verteporfin in patients with predominantly classic age-related macular degeneration.

Bansback N, Davis S, Brazier J.

Eye (Lond). 2007 Dec;21(12):1455-63. Epub 2006 Nov 10.PMID: 17086167 [PubMed - indexed for MEDLINE]Related articles

A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.

Brown MM, Brown GC, Brown HC, Peet J.

Ophthalmology. 2008 Jun;115(6):1039-1045.e5. Epub 2007 Nov 5.PMID: 17976724 [PubMed - indexed for MEDLINE]Related articles

[Cost-effectiveness of photodynamic therapy with verteporfin for choroidal neovascularization in age-related macular degeneration in routine clinical practice in Switzerland]

Donati G.

J Fr Ophtalmol. 2007 Oct;30(8):837-41. French. PMID: 17978682 [PubMed - indexed for MEDLINE]Related articlesFree article

[Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration]

Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.

Klin Monbl Augenheilkd. 2007 Sep;224(9):727-32. German. PMID: 17846963 [PubMed - indexed for MEDLINE]Related articles

Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS.

Pharmacoeconomics. 2007;25(10):863-79.PMID: 17887807 [PubMed - indexed for MEDLINE]Related articles

The goal of value-based medicine analyses: comparability. The case for neovascular macular degeneration.

Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S.

Trans Am Ophthalmol Soc. 2007;105:160-9; discussion 169-71.PMID: 18427606 [PubMed - indexed for MEDLINE]Related articlesFree article

[The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes]

Karel I.

Cesk Slov Oftalmol. 2007 Sep;63(5):311-9. Czech. PMID: 17915581 [PubMed - indexed for MEDLINE]Related articles

Improvement in quality of life from photodynamic therapy: a Canadian perspective.

Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM.

Can J Ophthalmol. 2001 Oct;36(6):332-8.PMID: 11714119 [PubMed - indexed for MEDLINE]Related articles

Quality of life in a prospective, randomised pilot-trial of photodynamic therapy versus full macular translocation in treatment of neovascular age-related macular degeneration--a report of 1 year results.

Lüke M, Ziemssen F, Bartz-Schmidt KU, Gelisken F.

Graefes Arch Clin Exp Ophthalmol. 2007 Dec;245(12):1831-6. Epub 2007 Mar 9.PMID: 17347809 [PubMed - indexed for MEDLINE]Related articles

Photodynamic therapy with verteporfin for choroidal neovascularization due to age-related macular degeneration and other causes: a New Zealand outcomes study.

Sharp DM, Lai S, Markey CM.

Clin Experiment Ophthalmol. 2007 Jan-Feb;35(1):24-31.PMID: 17300567 [PubMed - indexed for MEDLINE]Related articles